Insulin degludec

Drug Profile

Insulin degludec

Alternative Names: Insulin decludec; NN-1250; SIBA; Soluble insulin basal analogue; Tresiba

Latest Information Update: 03 Apr 2017

Price : $50

At a glance

  • Originator Novo Nordisk
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • No development reported Diabetes mellitus

Most Recent Events

  • 24 Mar 2017 Novo Nordisk expects final approval from the EMA for inclusion of data from the phase III SWITCH trials in the label of Insulin degludec for Type-1 and Type-2 diabetes mellitus in the European Union
  • 24 Mar 2017 The Committee for Medicinal Products for Human Use recommends update of the label for Insulin degludec to include data from the phase III SWITCH 1 and 2 clinical trials for Type-1 and Type-2 diabetes mellitus in the European Union
  • 13 Mar 2017 Novo Nordisk initiates a phase III trial for Type-2 diabetes mellitus in USA, Canada, Estonia, Denmark, Germany, Greece, Poland and Hungary (NCT03078478)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top